Literature DB >> 23906871

The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma.

Xiujuan Han1, Li Xue, Libin Zhou, Li Gong, Shaojun Zhu, Li Yao, Shumei Wang, Miao Lan, Yanhong Li, Wei Zhang.   

Abstract

OBJECTIVES: PTPN13 is a new candidate tumor-suppressing gene. To investigate the PTPN13 expression and its potential function in the invasion and metastasis of lung squamous cell carcinoma (LSCC), we performed this study in 91 primary LSCC tissues and the adjacent non-cancerous tissues.
METHODS: The mRNA expression of PTPN13 and FAK was quantitated by reverse transcription polymerase chain reaction. The protein expression of PTPN13, focal adhesion kinase (FAK) and phosphorylated FAK (P-FAK) was evaluated using immunohistochemical staining and western blotting. The association among PTPN13 expression, FAK expression and the clinicopathological parameters were analyzed.
RESULTS: PTPN13 expression was down-regulated in LSCC, and was negatively correlated with the cancer grade and stage. FAK mRNA, as well as FAK protein level was elevated in LSCC tissues. P-FAK level, also found increased, had no association with FAK mRNA and FAK protein expression, but had a negative correlation with the PTPN13 expression. P-FAK level had a significant positive correlation with the TNM classification.
CONCLUSION: The over-expression of FAK and increased FAK phosphorylation plays an important role in the invasion and metastasis of LSCC.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Focal adhesion kinase; Lung squamous cell carcinoma; PTPN13; Phosphorylation

Mesh:

Substances:

Year:  2013        PMID: 23906871     DOI: 10.1016/j.yexmp.2013.07.008

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  8 in total

1.  pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.

Authors:  Kamolrat Thanapprapasr; Adisak Nartthanarung; Duangmani Thanapprapasr; Artit Jinawath
Journal:  PLoS One       Date:  2017-08-28       Impact factor: 3.240

2.  High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome.

Authors:  Véronique D'Hondt; Magalie Lacroix-Triki; Marta Jarlier; Florence Boissiere-Michot; Carole Puech; Peter Coopman; Dionyssios Katsaros; Gilles Freiss
Journal:  Oncotarget       Date:  2017-09-21

3.  MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma.

Authors:  Li Zhuang; Tao Shou; Ke Li; Chun-Lin Gao; Lin-Can Duan; Li-Zhou Fang; Qin-Yong Zhang; Zong-Ning Chen; Chao Zhang; Shou-Tao Yang; Gao-Feng Li
Journal:  J Cell Mol Med       Date:  2017-06-27       Impact factor: 5.310

4.  PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness.

Authors:  Mohamed Hamyeh; Florence Bernex; Romain M Larive; Aurélien Naldi; Serge Urbach; Joelle Simony-Lafontaine; Carole Puech; William Bakhache; Jérome Solassol; Peter J Coopman; Wiljan J A J Hendriks; Gilles Freiss
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

Review 5.  Dual Role of the PTPN13 Tyrosine Phosphatase in Cancer.

Authors:  Soha Mcheik; Leticia Aptecar; Peter Coopman; Véronique D'Hondt; Gilles Freiss
Journal:  Biomolecules       Date:  2020-12-11

6.  High expression of phosphorylated focal adhesion kinase predicts a poor prognosis in human colorectal cancer.

Authors:  Guanyu Yu; Mengnan Xu; Leqi Zhou; Kuo Zheng; Xiaoming Zhu; Jinke Sui; Cheng Xin; Wenjun Chang; Wei Zhang; Fuao Cao
Journal:  Front Pharmacol       Date:  2022-09-13       Impact factor: 5.988

7.  miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13.

Authors:  Shudi Xu; Tao Wang; Zhiwei Yang; Ying Li; Weijie Li; Ting Wang; Shan Wang; Lintao Jia; Shengli Zhang; Shengqing Li
Journal:  Oncotarget       Date:  2016-07-19

8.  Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.

Authors:  Yongcong Yan; Pinbo Huang; Kai Mao; Chuanchao He; Qiaodong Xu; Mengyu Zhang; Haohan Liu; Zhenyu Zhou; Qiming Zhou; Qianlei Zhou; Bing Ou; Qinghua Liu; Jianhong Lin; Ruibin Chen; Jie Wang; Jianlong Zhang; Zhiyu Xiao
Journal:  Oncogene       Date:  2020-10-13       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.